Search - tctmd.com

Displaying 1 - 20 of 49

Sort: Relevancy | Date

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

Presentation AHA 2017

The POISE-2 PCI Substudy

Presenter: Michelle M. Graham

November 14, 2017

Presentation AHA 2017

Subgroup Analysis from the RE-DUAL PCI Trial

Presenter: Jonas Oldgren

November 14, 2017

Presentation AHA 2017

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Presenter: Zuzana Motovska

November 11, 2017

Presentation Cardiovascular Interventions 2017

DAPT Duration After Stenting: An Updated Appraisal

Presenter: Dean J. Kereiakes

November 09, 2017

Presentation

Lesion Complexity and Outcomes of Extended DAPT After PCI

October 23, 2017

Presentation

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

October 09, 2017

Presentation CDM 2017

From Andreas Gruentzig to PCSK9: How Angioplasty Transformed Cardiovascular Care

Presenter: Spencer B. King

October 06, 2017

Presentation CDM 2017

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Presenter: Robert A. Vogel

October 06, 2017

Presentation

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

October 03, 2017

Presentation VIVA 2017

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Presenter: William Gray

September 21, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

Presentation

Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54

September 12, 2017

Presentation iASSESS 2017

Stable Angina: PCI vs CABG vs OMT

Presenter: Robert T. Pyo

August 30, 2017

Presentation ESC 2017

Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-Segment Elevation

Presenter: Borja Ibanez

August 28, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

Presentation ESC 2017

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Presenter: David Erlinge

August 27, 2017

Presentation iASSESS 2017

STEMI: Treatment Strategies, Drugs And Devices

Presenter: Dharam J. Kumbhani

August 24, 2017

Advertisement

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

The POISE-2 PCI Substudy

Subgroup Analysis from the RE-DUAL PCI Trial

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

DAPT Duration After Stenting: An Updated Appraisal

Lesion Complexity and Outcomes of Extended DAPT After PCI

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

From Andreas Gruentzig to PCSK9: How Angioplasty Transformed Cardiovascular Care

Can Heart Disease be Eventually Abolished? The PCSK9 Revolution

Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54

Stable Angina: PCI vs CABG vs OMT

Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-Segment Elevation

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

STEMI: Treatment Strategies, Drugs And Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content